Keyword: Samsung Bioepis

China fines vaccine scandal-hit Changsheng $1.3 billion; Merck and Samsung bail on a Lantus biosim; Taiho grows VC fund to sixfold.

Merck canceled its partnership with Samsung Bioepis for a Lantus biosimilar after facing hurdles with pricing and production costs.

A Takeda founder descendant blasts the Shire deal, as the company moves its U.S. HQ closer to Shire; Sanofi revamps two global units.

Roche is battling competition from Herceptin biosimilars and has reportedly sued Bioepis over its biosimilar as it heads for the finish line.

Samsung BioLogics is slated to get a piece of the $22 billion investment Samsung says it will invest in growth businesses.

Korean CDMO Samsung BioLogics has won FDA approval for its first finished product at the second of three plants built in rapid succession.  

Biogen and Eisai's anti-amyloid candidate shows promise; Otsuka signs two M&A deals; Samsung BioLogics faces criminal probe over Biogen JV agreement.

South Korean regulators have ruled on a case of alleged accounting violations at Samsung BioLogics and sent their findings to prosecutors.

Sanofi launches a big data-focused global R&D hub in China; Takeda looks to sell its old HQ for $542 million; I-Mab gets $220 million in series C.

Biogen will pay about $700 million to boost its stake in Samsung Bioepis to 49.9%. It currently owns 5.4% of the biosimilars joint venture.